Cargando…

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

PURPOSE: Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Michael L., Jurczak, Wojciech, Zinzani, Pier Luigi, Eyre, Toby A., Cheah, Chan Y., Ujjani, Chaitra S., Koh, Youngil, Izutsu, Koji, Gerson, James N., Flinn, Ian, Tessoulin, Benoit, Alencar, Alvaro J., Ma, Shuo, Lewis, David, Lech-Maranda, Ewa, Rhodes, Joanna, Patel, Krish, Maddocks, Kami, Lamanna, Nicole, Wang, Yucai, Tam, Constantine S., Munir, Talha, Nagai, Hirokazu, Hernandez-Ilizaliturri, Francisco, Kumar, Anita, Fenske, Timothy S., Seymour, John F., Zelenetz, Andrew D., Nair, Binoj, Tsai, Donald E., Balbas, Minna, Walgren, Richard A., Abada, Paolo, Wang, Chunxiao, Zhao, Junjie, Mato, Anthony R., Shah, Nirav N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	RAPID COMMUNICATIONS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461952/ https://www.ncbi.nlm.nih.gov/pubmed/37192437 http://dx.doi.org/10.1200/JCO.23.00562

Ejemplares similares

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT
por: Jurczak, Wojciech, et al.
Publicado: (2023)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Scarfò, Lydia, et al.
Publicado: (2023)

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
por: Jurczak, Wojciech, et al.
Publicado: (2023)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Eyre, T. A., et al.
Publicado: (2022)

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
por: Cohen, Jonathon, et al.
Publicado: (2023)

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
por: Aslan, Burcu, et al.
Publicado: (2022)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
por: Eyre, T. A., et al.
Publicado: (2022)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
por: Lamanna, Nicole, et al.
Publicado: (2023)

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
por: Jurczak, W., et al.
Publicado: (2022)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
por: Thompson, Philip A., et al.
Publicado: (2023)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
por: Eyre, Toby A., et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

Primary effusion lymphoma: current perspectives
por: Narkhede, Mayur, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2020)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Correction: Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2021)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
por: Guinn, Daphne, et al.
Publicado: (2014)

Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
por: Hess, Lisa M., et al.
Publicado: (2022)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g3k4hr6q6tdb68ac0h1i502o39